Curriculum vitae

Curriculum Vitae
1995-2002: Medical Doctor, Universiteit Gent, magna cum laude Principles of Electrocardiography (ECG), Universiteit Gent 2002-2003: Diplome of Tropical Medicine, Prins Leopold Instituut voor Tropische Basics of Statistical Inference, Universiteit Gent Laboratory Animal Scientist (FELASA Category C), Basic Course in Laboratory Animal Science, Universiteit Gent Diploma Good Clinical Practice (GCP), Universitair Ziekenhuis Gent 4/2003-9/2008:Specialist Training in Internal Medicine, Department of Internal Medicine, Trainee in Tropical Medicine, Universitair Ziekenhuis van Antwerpen 2003-2007: Ph. D. fellowship of the Research Foundation - Flanders (FWO), at the Center for Vaccinology, Ghent University. Project Title “The human liver uPA-SCID model: exploration and use for the study of anti-hepatitis C methods.” 2003-2007: Co-investigator for phase 1 and 2 clinical vaccine trials Tutor “Infection and Immunity” (1st Bachelor of Medicine) and “Clinical Medicine” (3rd Bachelor of Medicine) 2007-2008: Trainee in Internal Medicine, Maria Middelares Ziekenhuis Gent 10/2008-…: Specialist Training in Gastroenterology, Universitair Ziekenhuis Gent. 10-12/2008: Study Visit at the Laboratory of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Nederland; with a Travel Bursary of the Research Project Title “Flowcytometry on fine needle aspiration biopsies from the liver to characterise the intrahepatic immune response in chronic viral hepatitis.” 10-12/2008: Trainee in Hepatology, Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Nederland. Supervisor: Dr. RA De Man Trainee in Gastroenterology and Hepatology, Universitair Ziekenhuis Gent. Trainee in Gastroenterology, Heilig Hart Ziekenhuis Roeselare. 1. Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL.
Hepatology. 2009 Nov;50(5):1646-55. 2. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H,
Leroux-Roels G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 2008 Dec;48(6):1761-8. 3. Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH,
Leroux-Roels G. Polyclonal immunoglobulins from a chronic HCV patient protect human liver-chimeric mice from infection with a homologous HCV strain. Hepatology. 2008 4. Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G.
Ultra-Rapid Cardiotoxicity of the Hepatitis C Virus Protease Inhibitor BILN 2061 in the Urokinase-Type Plasminogen Activator Mouse. Gastroenterology. 2007 Oct;133(4):1144-55. Epub 2007 Jul 10. 5. Leroux-Roels I, Borowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster
JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pademic influenza vaccine: a randomised controlled trial. Lancet. 2007 BII expression levels modulate hepatitis C virus infectivity. J Virol. 2007 Apr;81(7):3162- hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U Stevens-Johnson syndrome. Infection. 2004 Oct;32(5):306-7. indinavir-induced thrombocytopenia in a patient with HIV infection. Int J Infect Dis. 2004 Submitted to Journal of Hepatology. C2 abstracts (oral or poster presentations on international congresses) 1. Meuleman P, Bukh J, Desombere I, Vanwolleghem T, Verhoye L, Farhoudi A, Alter H,
Purcell RH, Leroux-Roels G. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal anti-HCV antibodies in chimeric mice. 16th International Symposium on Hepatitis C Virus and Related Viruses. Nice, France, October 3rd-7th, 2009. (poster) 2. Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH,
Leroux-Roels G. Administration of polyclonal antibodies from patient H partially protects human liver-chimeric mice from infection with the homologous H77C virus. 14th International Symposium on Hepatitis C and Related Viruses. Glasgow, Scotland, UK, 3. Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. The
human liver uPA-SCID Mouse Model allows for the Rapid Detection of Antiviral and Cardiotoxic effects of BILN2061. 13th International Meeting on Hepatitis C Virus and Related Viruses. Cairns, Australia, August 27th-31st, 2006. (oral) 4. Vanwolleghem T, Meuleman P, De Vos R, Libbrecht L, Roskams T, Leroux-Roels G.
Antiviral and Cardiotoxic Effects of BILN2061 in uPA-SCID mice. 12th International Symposium on Viral Hepatitis and Liver Disease. Paris, France, July 1st-5th, 2006.(oral) 5. Meuleman P, Vanwolleghem T, Leroux-Roels G. The human liver-uPA-SCID mouse: a
chimeric rodent model for the study of viral hepatitis. 12th International Symposium on Viral Hepatitis and Liver Disease. Paris, France, July 1st-5th, 2006. (oral) 6. Leroux-Roels G, Clément F, Desombere I, Meuleman P, Vanwolleghem T. A Vaccine for
HCV: Do we need it, Can we make it? Virology Africa 2005. Cape Town, South-Africa, November 8th-11th, 2005. (oral) 7. Lindenbach BD, Meuleman P, Vanwolleghem T, Ploss A, Syder AJ, McKeating JA,
Lanford R, Feinstone SM, Major ME, Leroux-Roels G, Rice CM. Cell culture produced HCV is highly infectious in vitro and in vivo. 12th International Symposium on Hepatitis C and Related Viruses. Montréal, Canada, October 2nd-6th, 2005.(oral) 8. Borkowski A, Leroux-Roels I, Baras B, Hons E, Vanwolleghem T, Neumeier E, Devaster
JM, Leroux-Roels G. Antigen sparing effect of a novel adjuvant system in a split H5N1 pandemic influenza vaccine. Biennal International Conference on Influenza Vaccines for the World – IVW2006. The World Influenza Vaccination Conference; 18-20 October, 2006, 9. Leroux-Roels I, Borkowski A, Dramé M, Hons E, Vanwolleghem T, Bernhard R, Leroux-
Roels G. Pandemic influenza preparedness: cross-reactive immunity with an adjuvanted H5N1 candidate vaccine. IX International Conference for Respiratory Viral Infections, Causeway Bay, Hong Kong; March 3-6, 2007 (oral). 10. Moris P, Leroux-Roels I, Dramé M, Clement F, Vanwolleghem T, Saenger R, Leroux-
Roels G, Van Mechelen M, Hanon E. Heterologous cell-mediated immunity priming using adjuvanted H5N1 candidate vaccine. IX International Conference for Respiratory Viral Infections, Causeway Bay, Hong Kong; March 3-6, 2007 (oral presentation by Martine 11. Leroux-Roels I, Moris P, Clement F, Hons E, Vanwolleghem T, Bernhard R, Van
Mechelen M, Leroux-Roels G. Pandemic influenza preparation: cross-reactive immunity with an adjuvanted H5N1 candidate vaccine. Anti-Avian Influenza 2007, Paris, France; 31 12. Leroux-Roels I, Moris P, Dramé M, Clement F, Hons E, Vanwolleghem T, Bernhard R,
Van Mechelen M, Leroux-Roels G. Cross-reactive humoral and cell-mediated immunity with an adjuvanted H5N1 candidate vaccine. Options for the Control of Influenza VI Conference, Toronto, Canada; 17-23 June 2007 (poster). 13. Leroux-Roels I, Moris P, Clement F, Vanwolleghem T, Hons E, Durand C, Oostvogels L,
Devaster JM, Leroux-Roels G, M. Van Mechelen. Marked long lasting anti-influenza cell- mediated immunity induced by an adjuvanted influenza vaccine in elderly. Infectious Diseases Society of America (IDSA), 45th Annual Meeting, San Diego, USA, October 4-7, 14. Leroux-Roels I, Moris P, Clement F, Hons E, Vanwolleghem T, Bernhard R, Van
Mechelen M, Leroux-Roels G. Pandemic influenza preparation: cross-reactive immunity with an adjuvanted H5N1 candidate vaccine associated with a good safety profile. Vaccine Congress, Amsterdam, Netherlands, December 9-11, 2007 (oral). £500 Bursary for the 14th International Meeting on Hepatitis C Virus and Related Viruses. Glasgow, Scotland, UK, September 9th-13th, 2007.

Source: http://www.fnrs.be/uploaddocs/docs/COMMUNIQUER/FRS-FNRS_CV_Vanwolleghem.pdf